Affimed (NASDAQ:AFMD) Earns Hold Rating from Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Affimed (NASDAQ:AFMD – Get Rating) in a report issued on Thursday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Several other research firms have also recently weighed in on AFMD. Wells Fargo & Company lowered their price target on Affimed from $8.00 to $7.00 and set an “overweight” rating on the stock in a report on Monday, December 12th. Truist Financial lowered their price target on Affimed from $12.00 to $8.00 in a report on Monday, December 12th. Piper Sandler lowered their price target on Affimed from $7.00 to $6.00 and set an “overweight” rating on the stock in a report on Monday, December 12th. HC Wainwright began coverage on Affimed in a report on Monday, December 12th. They set a “buy” rating and a $6.00 price target on the stock. Finally, SVB Leerink lowered their price target on Affimed from $10.00 to $6.00 and set an “outperform” rating on the stock in a report on Monday, December 12th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Affimed currently has an average rating of “Moderate Buy” and a consensus price target of $5.83.

Affimed Stock Performance

AFMD stock opened at $0.76 on Thursday. The stock has a market capitalization of $93.80 million, a PE ratio of -1.21 and a beta of 2.58. Affimed has a 12-month low of $0.74 and a 12-month high of $5.10. The company has a current ratio of 5.65, a quick ratio of 5.63 and a debt-to-equity ratio of 0.07. The stock’s 50 day simple moving average is $1.04 and its 200 day simple moving average is $1.59.

Hedge Funds Weigh In On Affimed

Institutional investors have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD increased its stake in Affimed by 30.9% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 13,570 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 3,202 shares in the last quarter. Vanguard Group Inc. increased its stake in Affimed by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 1,386,701 shares of the biopharmaceutical company’s stock worth $6,060,000 after buying an additional 5,499 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Affimed by 1.9% in the 1st quarter. Bank of New York Mellon Corp now owns 302,737 shares of the biopharmaceutical company’s stock worth $1,323,000 after buying an additional 5,513 shares in the last quarter. Ronald Blue Trust Inc. purchased a new stake in Affimed in the 2nd quarter worth $26,000. Finally, Advisor Group Holdings Inc. increased its stake in Affimed by 258.3% in the 1st quarter. Advisor Group Holdings Inc. now owns 8,967 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 6,464 shares in the last quarter. 61.73% of the stock is owned by institutional investors.

About Affimed

(Get Rating)

Affimed NV engages in the discovery and development of cancer immunotherapies. It is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs.